Quarterly ResultMay 6, 2026, 04:53 PM
Acadia Pharmaceuticals Q1 Revenue $268M; DAYBUE Sales $101M
AI Summary
Acadia Pharmaceuticals reported solid first-quarter 2026 financial results, with total revenues increasing 10% year-over-year to $268 million. This growth was driven by strong sales of DAYBUE, which rose 20% to $101 million, and NUPLAZID, which increased 6% to $167 million. The company also reaffirmed its full-year 2026 financial guidance and provided positive updates on the DAYBUE STIX launch and pipeline progress for remlifanserin and trofinetide in Japan.
Key Highlights
- Total revenues were $268 million, up 10% from $244 million in Q1 2025.
- DAYBUE net sales reached $101 million, a 20% increase year-over-year.
- NUPLAZID net sales were $167 million, up 6% year-over-year.
- Net income for Q1 2026 was $4 million, or $0.02 per diluted share.
- Cash, cash equivalents, and investment securities totaled $851 million.
- Reaffirmed 2026 total revenue guidance of $1.22 to $1.28 billion.
- Reaffirmed 2026 DAYBUE net sales guidance of $460 to $490 million.
- Reaffirmed 2026 NUPLAZID net sales guidance of $760 to $790 million.